Pds Biotechnology Corporation Financials
This page shows Pds Biotechnology Corporation (PDSB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External funding, not product revenue, still runs the business as cash burn tracks operating losses almost one-for-one.
In FY2025, operating cash flow and free cash flow were both-$27.8M because capital spending was$0 . With EBITDA still-$31.5M and depreciation only$61K , reported losses are translating almost directly into cash use, so the financing need is operational rather than a byproduct of heavy assets or accounting noise.
Leverage ratios look worse even though the liability stack is not expanding, with debt-to-equity at 2.3x and total liabilities at
The lower burn partly reflects a smaller R&D program, not self-funding scale: research and development fell to
Financial Health Signals
Pds Biotechnology Corporation does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Pds Biotechnology Corporation passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Pds Biotechnology Corporation reported a net loss of $34.5M while operations used $27.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Pds Biotechnology Corporation reported an operating loss of $31.5M against $5.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Pds Biotechnology Corporation's EBITDA was -$31.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 13.2% from the prior year.
Pds Biotechnology Corporation reported -$34.5M in net income in fiscal year 2025. This represents an increase of 8.3% from the prior year.
Pds Biotechnology Corporation earned -$0.74 per diluted share (EPS) in fiscal year 2025. This represents an increase of 28.2% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Pds Biotechnology Corporation recorded an outflow of $27.8M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 20.8% from the prior year.
Pds Biotechnology Corporation held $26.7M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Pds Biotechnology Corporation's ROE was -372.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 174.9 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Pds Biotechnology Corporation invested $19.0M in research and development in fiscal year 2025. This represents a decrease of 15.7% from the prior year.
Pds Biotechnology Corporation reported no capital expenditure in fiscal year 2025. This represents a decrease of 100.0% from the prior year.
Not reported for fiscal year 2025.
PDSB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | N/A | $19.0M-15.7% | $22.6M-18.7% | $27.8M-5.7% | $29.4M+161.5% | $11.3M+42.0% | $7.9M+29.9% | $6.1M | N/A | $34.3M+38.2% | $24.8M+39.2% | $17.8M+110.5% | $8.5M+89.0% | $4.5M |
| SG&A Expenses | N/A | $12.5M-9.0% | $13.8M-10.0% | $15.3M+24.8% | $12.2M+20.2% | $10.2M+46.0% | $7.0M-36.5% | $11.0M | N/A | $17.7M+20.2% | $14.7M+69.6% | $8.7M+83.4% | $4.7M+135.6% | $2.0M |
| Operating Income | N/A | -$31.5M+13.2% | -$36.3M+15.6% | -$43.0M-3.3% | -$41.7M-94.4% | -$21.4M-43.9% | -$14.9M+29.2% | -$21.0M | N/A | -$52.0M-31.5% | -$39.5M-49.1% | -$26.5M-100.8% | -$13.2M-103.4% | -$6.5M |
| Interest Expense | N/A | $5.3M+14.6% | $4.7M+10.8% | $4.2M+219.5% | $1.3M | $0 | $0-100.0% | $34K+833.5% | $4K-99.8% | $2.2M+81.1% | $1.2M+47.4% | $816K+345.7% | $183K+5361.5% | $3K |
| Income Tax | N/A | -$1.2M-34.6% | -$869K+38.2% | -$1.4M-17.3% | -$1.2M+73.5% | -$4.5M | $0+100.0% | -$382K | $0+100.0% | -$2.6M-40.1% | -$1.8M-66.7% | -$1.1M-87.5% | -$591K-28.7% | -$459K |
| Net Income | -$33.7M | -$34.5M+8.3% | -$37.6M+12.4% | -$42.9M-5.1% | -$40.9M-141.5% | -$16.9M-13.9% | -$14.8M-112.1% | -$7.0M | N/A | -$50.9M-31.0% | -$38.8M-38.3% | -$28.1M-130.1% | -$12.2M-77.3% | -$6.9M |
| EPS (Diluted) | — | -$0.74+28.2% | -$1.03+25.9% | -$1.39+2.8% | -$1.43-116.7% | -$0.66 | -$0.89 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
PDSB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $30.5M-32.8% | $45.4M-23.6% | $59.4M-22.9% | $77.0M+14.6% | $67.2M+117.5% | $30.9M+113.2% | $14.5M+8713.0% | $164K-99.8% | $92.6M-16.5% | $110.9M-17.3% | $134.1M+696.0% | $16.8M | N/A |
| Current Assets | $28.3M-37.3% | $45.1M-23.7% | $59.1M-22.8% | $76.5M+14.4% | $66.8M+120.3% | $30.3M+109.7% | $14.5M+11748.9% | $122K-99.9% | $89.1M-17.0% | $107.4M-18.2% | $131.3M+755.3% | $15.3M | N/A |
| Cash & Equivalents | $26.7M-35.9% | $41.7M-26.3% | $56.6M-23.4% | $73.8M+13.1% | $65.2M+126.2% | $28.8M+137.1% | $12.2M+11628.4% | $104K-99.9% | $88.1M-17.2% | $106.4M-18.3% | $130.2M+848.3% | $13.7M+74.7% | $7.9M |
| Total Liabilities | $21.2M-19.4% | $26.4M-20.8% | $33.3M+0.8% | $33.0M+727.7% | $4.0M+6.0% | $3.8M+34.6% | $2.8M+25.2% | $2.2M-97.6% | $93.2M+330.9% | $21.6M+86.3% | $11.6M-74.0% | $44.7M | N/A |
| Current Liabilities | $9.5M-44.5% | $17.1M+25.4% | $13.6M+38.8% | $9.8M+161.5% | $3.8M+14.8% | $3.3M+17.1% | $2.8M+46.3% | $1.9M-85.2% | $12.9M+92.5% | $6.7M-22.2% | $8.6M+120.6% | $3.9M | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $5.5M | N/A | N/A |
| Total Equity | $9.3M-51.3% | $19.0M-27.3% | $26.1M-40.6% | $44.0M-30.4% | $63.2M+133.0% | $27.1M+131.9% | $11.7M+666.1% | -$2.1M-239.0% | -$610K-100.7% | $89.3M-27.1% | $122.5M+540.0% | -$27.8M-81.3% | -$15.3M |
| Retained Earnings | -$216.6M-18.9% | -$182.1M-26.0% | -$144.5M-42.3% | -$101.6M-67.3% | -$60.7M-38.6% | -$43.8M-51.3% | -$28.9M-31.9% | -$21.9M+85.6% | -$151.9M-50.3% | -$101.1M-62.4% | -$62.3M-108.8% | -$29.8M | N/A |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
PDSB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$16.8M | -$27.8M+20.8% | -$35.0M-4.1% | -$33.6M-30.8% | -$25.7M-105.9% | -$12.5M+5.0% | -$13.1M+27.2% | -$18.1M | N/A | -$40.7M-26.4% | -$32.2M-48.0% | -$21.8M-123.9% | -$9.7M-20.8% | -$8.0M |
| Capital Expenditures | N/A | $0-100.0% | $29K | $0 | N/A | N/A | N/A | N/A | $0-100.0% | $189K-72.5% | $687K-47.4% | $1.3M+47.5% | $885K+546.3% | $137K |
| Free Cash Flow | N/A | -$27.8M+20.8% | -$35.1M-4.2% | -$33.6M | N/A | N/A | N/A | N/A | N/A | -$40.9M-24.4% | -$32.9M-42.6% | -$23.1M-117.5% | -$10.6M-29.6% | -$8.2M |
| Investing Cash Flow | N/A | $0+100.0% | -$29K | $0 | N/A | N/A | $0-100.0% | $29.4M | $0+100.0% | -$189K+72.5% | -$687K+47.4% | -$1.3M | N/A | N/A |
| Financing Cash Flow | -$9.5M | $12.8M-36.7% | $20.2M+23.3% | $16.4M-52.2% | $34.3M-29.9% | $48.9M+63.9% | $29.8M+3876.9% | $750K | N/A | $22.6M+148.3% | $9.1M-93.5% | $139.5M | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
PDSB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity | -372.8%-174.9pp | -197.9%-33.6pp | -164.3%-71.5pp | -92.8%-66.1pp | -26.8%+28.0pp | -54.7%+5.1pp | -59.8% | N/A | N/A | -43.5%-20.6pp | -22.9% | N/A | N/A |
| Return on Assets | -113.1%-30.2pp | -82.9%-10.6pp | -72.3%-19.3pp | -53.0%-27.9pp | -25.2%+22.9pp | -48.1%+0.2pp | -48.3% | N/A | -54.9%-19.9pp | -35.0%-14.1pp | -20.9%+51.5pp | -72.4% | N/A |
| Current Ratio | 2.98+0.3x | 2.64-1.7x | 4.33-3.5x | 7.79-10.0x | 17.80+8.5x | 9.28+4.1x | 5.18+5.1x | 0.06-6.9x | 6.92-9.1x | 16.06+0.8x | 15.28+11.3x | 3.94 | N/A |
| Debt-to-Equity | 2.30+0.9x | 1.39+0.1x | 1.27+0.5x | 0.75+0.7x | 0.06-0.1x | 0.14-0.1x | 0.24 | N/A | N/A | 0.24+0.2x | 0.04 | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Pds Biotechnology Corporation Ranks
Frequently Asked Questions
Is Pds Biotechnology Corporation profitable?
No, Pds Biotechnology Corporation (PDSB) reported a net income of -$34.5M in fiscal year 2025.
What is Pds Biotechnology Corporation's EBITDA?
Pds Biotechnology Corporation (PDSB) had EBITDA of -$31.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Pds Biotechnology Corporation's return on equity (ROE)?
Pds Biotechnology Corporation (PDSB) has a return on equity of -372.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Pds Biotechnology Corporation's free cash flow?
Pds Biotechnology Corporation (PDSB) recorded an outflow of $27.8M in free cash flow during fiscal year 2025. This represents a 20.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Pds Biotechnology Corporation's operating cash flow?
Pds Biotechnology Corporation (PDSB) recorded an outflow of $27.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Pds Biotechnology Corporation's total assets?
Pds Biotechnology Corporation (PDSB) had $30.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Pds Biotechnology Corporation's capital expenditures?
Pds Biotechnology Corporation (PDSB) reported no capital expenditure during fiscal year 2025.
How much does Pds Biotechnology Corporation spend on research and development?
Pds Biotechnology Corporation (PDSB) invested $19.0M in research and development during fiscal year 2025.
What is Pds Biotechnology Corporation's current ratio?
Pds Biotechnology Corporation (PDSB) had a current ratio of 2.98 as of fiscal year 2025, which is generally considered healthy.
What is Pds Biotechnology Corporation's debt-to-equity ratio?
Pds Biotechnology Corporation (PDSB) had a debt-to-equity ratio of 2.30 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Pds Biotechnology Corporation's return on assets (ROA)?
Pds Biotechnology Corporation (PDSB) had a return on assets of -113.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Pds Biotechnology Corporation's cash runway?
Based on fiscal year 2025 data, Pds Biotechnology Corporation (PDSB) had $26.7M in cash against an annual operating cash burn of $27.8M. This gives an estimated cash runway of approximately 12 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Pds Biotechnology Corporation's Piotroski F-Score?
Pds Biotechnology Corporation (PDSB) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Pds Biotechnology Corporation's earnings high quality?
Pds Biotechnology Corporation (PDSB) reported a net loss of $34.5M while operations used $27.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Pds Biotechnology Corporation cover its interest payments?
Pds Biotechnology Corporation (PDSB) reported an operating loss of $31.5M against $5.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.